Invivyd, Inc. (IVVD)

Market Cap	61.18M
Revenue (ttm)	25.38M
Net Income (ttm)	-169.93M
Shares Out	119.96M
EPS (ttm)	-1.43
PE Ratio	n/a
Forward PE	4.50
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,633,121
Open	0.4990
Previous Close	0.4713
Day's Range	0.4755 - 0.5081
52-Week Range	0.3550 - 2.7400
Beta	0.41
Analysts	Strong Buy
Price Target	7.52 (+1,374.51%)
Earnings Date	May 8, 2025

About IVVD

Invivyd, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. It developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering. The company’s pipeline includes PEMGRADA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate which is in preclinical studies f...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Aug 6, 2021
• Employees: 100
• Stock Exchange: NASDAQ
• Ticker Symbol: IVVD
• Website: https://invivyd.com

Analyst Forecast

According to 3 analysts, the average rating for IVVD stock is "Strong Buy." The 12-month stock price forecast is $7.52, which is an increase of 1,374.51% from the latest price.

Price Target

$7.52

(1,374.51% upside)

Analyst Consensus: Strong Buy